Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: A non-randomized comparison

Antiviral Therapy

Volumn 11, Issue 5, 2006, Pages 609-618

  De Luca, Andrea ^a   Cozzi Lepri, Alessandro ^b   Antinori, Andrea ^c   Zaccarelli, Mauro ^c   Bongiovanni, Marco ^d   Di Giambenedetto, Simona ^a   Marconi, Patrizia ^c   Cicconi, Paolo ^d   Resta, Francesco ^e   Grisorio, Benvenuto ^f   Ciardi, Maria ^g   Cauda, Roberto ^a   Monforte, Antonella D'Arminio ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SS Annunziata Hospital   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERTRIGLYCERIDEMIA; ITALY; MALE; MIDDLE AGED; NUCLEOSIDES; PROSPECTIVE STUDIES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT FAILURE; VIRAL LOAD;

EID: 33747811845     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
2. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 79:717-720.
3. Walmsley S, Bernstein B, King M, et al; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
4. Robbins GK, De Gruttola V, Shafer RW, et al.; AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
5. Gulick RM, Ribaudo HJ, Shikuma CM, et al.; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
6. van Leth F, Phanuphak P, Ruxrungtham K, et al.; 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
7. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 6 October 2005. A Service of the U.S Department of Health and Human Services. Available at: http://aidsinfo.nih.gov (last access 28 November 2005).
8. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
9. Gazzard B, BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2005; 6(Suppl 2):1-61.
10. Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, et al.; ICONA Study Group. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 2001; 15:983-990.
11. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269:729-730.
12. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel III Report. Bethesda, MD: National Heart, Lung and Blood Institute National Heart, Lung and Blood Institute; 2001. Publication 01-3095. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm (last access 28 November 2005).
13. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
14. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
15. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-2281.
16. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13:2075-2082
17. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Can Med Assoc J 2003; 169:656-661.
18. Sterne JA, Hernan MA, Ledergerber B, et al. Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
19. Pulido F, Arribas JR, Miro JM, et al.; EfaVIP Cohort Study Group. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004; 35:343-350.
20. Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS 2004; 18:2331-2333.
21. Torti C, Maggiolo F, Patroni A, et al.; MASTER Cohort. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother 2005; 56:190-195.
22. d'Arminio Monforte A, Cozzi-Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507.
23. Gallant JE, Staszewski S, Pozniak AL, et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
24. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189.
25. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284.
26. Wood E, Hogg RS, Heath KV, et al. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. AIDS 2003; 17:2629-2634.
27. Madge S, Mocroft A, Wilson D, et al. Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Med 2000; 1:212-218.
28. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
29. Phillips AN, Dunn D, Sabin C, et al. UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487-494.